220 related articles for article (PubMed ID: 31929398)
1. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine.
Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R
Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398
[TBL] [Abstract][Full Text] [Related]
2. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN
Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214
[TBL] [Abstract][Full Text] [Related]
3. Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis.
Zhang H; Kalluri HV; Bastian JR; Chen H; Alshabi A; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2018 Sep; 84(9):2075-2087. PubMed ID: 29873094
[TBL] [Abstract][Full Text] [Related]
4. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.
Concheiro M; Jones HE; Johnson RE; Choo R; Huestis MA
Ther Drug Monit; 2011 Oct; 33(5):619-26. PubMed ID: 21860340
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.
Kacinko SL; Jones HE; Johnson RE; Choo RE; Concheiro-Guisan M; Huestis MA
Clin Chem; 2009 Jun; 55(6):1177-87. PubMed ID: 19325013
[TBL] [Abstract][Full Text] [Related]
6. Simplified processing and rapid quantification of buprenorphine, norbuprenorphine, and their conjugated metabolites in human plasma using UPLC-MS/MS: Assessment of buprenorphine exposure during opioid use disorder treatment.
Zhao W; Alshogran OY; Zhang H; Joshi A; Krans EE; Caritis S; Shaik IH; Venkataramanan R
J Mass Spectrom; 2024 Apr; 59(4):e5015. PubMed ID: 38501738
[TBL] [Abstract][Full Text] [Related]
7. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.
Caritis SN; Bastian JR; Zhang H; Kalluri H; English D; England M; Bobby S; Venkataramanan R
Am J Obstet Gynecol; 2017 Oct; 217(4):459.e1-459.e6. PubMed ID: 28669739
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatographic/electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma.
Murphy CM; Huestis MA
J Mass Spectrom; 2005 Jan; 40(1):70-4. PubMed ID: 15637731
[TBL] [Abstract][Full Text] [Related]
9. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Moody DE; Fang WB; Chodkowski D; Andrews L; Friedland GH
Am J Drug Alcohol Abuse; 2011 Jul; 37(4):224-8. PubMed ID: 21438849
[TBL] [Abstract][Full Text] [Related]
10. Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.
Strang J; Reed K; Bogdanowicz K; Bell J; van der Waal R; Keen J; Beavan P; Baillie S; Knight A
Eur Addict Res; 2017; 23(2):61-70. PubMed ID: 28268215
[TBL] [Abstract][Full Text] [Related]
11. Confirmatory analysis of buprenorphine, norbuprenorphine, and glucuronide metabolites in plasma by LCMSMS. Application to umbilical cord plasma from buprenorphine-maintained pregnant women.
Concheiro M; Jones H; Johnson RE; Shakleya DM; Huestis MA
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(1):13-20. PubMed ID: 19945361
[TBL] [Abstract][Full Text] [Related]
12. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
[TBL] [Abstract][Full Text] [Related]
13. Clearance of buprenorphine during pregnancy and neonatal outcomes.
Coker JL; Ray-Griffith SL; McLeod C; Han X; Mancino M; Kearns GL; Stowe ZN
Arch Womens Ment Health; 2021 Dec; 24(6):933-939. PubMed ID: 33864131
[TBL] [Abstract][Full Text] [Related]
14. Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Moore K; Magee M; Sevinsky H; Chang M; Lubin S; Myers E; Ackerman P; Llamoso C
Br J Clin Pharmacol; 2019 Aug; 85(8):1771-1780. PubMed ID: 30980734
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry.
Concheiro M; Shakleya DM; Huestis MA
Forensic Sci Int; 2009 Jul; 188(1-3):144-51. PubMed ID: 19406593
[TBL] [Abstract][Full Text] [Related]
17. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry.
Huang W; Moody DE; McCance-Katz EF
Ther Drug Monit; 2006 Apr; 28(2):245-51. PubMed ID: 16628138
[TBL] [Abstract][Full Text] [Related]
18. Transplacental transfer and metabolism of buprenorphine in preterm human placenta.
Fokina VM; Patrikeeva SL; Zharikova OL; Nanovskaya TN; Hankins GV; Ahmed MS
Am J Perinatol; 2011 Jan; 28(1):25-32. PubMed ID: 20607647
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.
Hakomäki H; Kokki H; Lehtonen M; Ranta VP; Räsänen J; Voipio HM; Kokki M
Pharmacol Res Perspect; 2021 Apr; 9(2):e00726. PubMed ID: 33619904
[TBL] [Abstract][Full Text] [Related]
20. Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations.
Winhusen T; Lofwall M; Jones HE; Wilder C; Lindblad R; Schiff DM; Wexelblatt S; Merhar S; Murphy SM; Greenfield SF; Terplan M; Wachman EM; Kropp F; Theobald J; Lewis M; Matthews AG; Guille C; Silverstein M; Rosa C
Contemp Clin Trials; 2020 Jun; 93():106014. PubMed ID: 32353544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
